NIH CounterACT Program
“The CounterACT Program supports basic and translational research aimed at the identification of better therapeutic medical countermeasures against chemical threat agents, and facilitates their movement through the drug development and regulatory process in collaboration with other federal partner departments, agencies, and initiatives.” (9/24/18 – See NIH CounterACT Program)
Other funded CounterACT Research Centers of Excellence include:
UMDNJ/Rutgers University CounterACT Research Center of Excellence
Jeffrey D. Laskin, Ph.D.
RBHS-School of Public Health
U54AR055073
Development of Antidotes for Toxic Gases
Carl W. White, M.D.
University of Colorado, Denver
U54ES027698
Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication
Pamela J. Lein, Ph.D.
University of California, Davis
U54NS079202
Advancing Novel Cyanide Countermeasures
Calum A. MacRae, M.D., Ph.D.
Brigham and Women’s Hospital
U54NS112107
Barrier Damage and The Immune Cascade Northwestern University CounterACT Center of Excellence
Kurt Lu, MD
Northwestern University at Chicago
U54AR079795
